Eyenovia
  • Home
  • About
    • About Eyenovia
    • Vision
    • Leadership
  • Technology
  • Pipeline
    • Eyenovia Pipeline
    • MydCombi (Mydriasis)
    • MicroLine (Presbyopia)
    • MicroPine (Myopia)
  • Partners
  • Investors
  • News + Resources
    • News
    • Resource Library
  • Menu Menu

Potential Lost Productivity Resulting from the Global Burden of Myopia

Myopia Control 2020–Where are we and where are we heading

Juvenile Myopia Progression, Risk Factors and Interventions

Five Year Clinical Trial on Atropine for the Treatment of Myopia 2

Facing the Myopia Epidemic

Atropine for treatment of childhood myopia in India (I-Atom)

Recent Posts

  • Eyenovia Announces FDA Approval of Mydcombiâ„¢, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform May 8, 2023
  • Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update March 30, 2023
  • Eyenovia Announces Independent Director Stephen Benjamin To Step Down To Assume Role Of Head Of White House’s Office Of Public Engagement March 2, 2023

Pipeline and Technology

  • MydCombi (Mydriasis)
  • MicroLine (Presbyopia)
  • MicroPine (Myopia)
  • Technology

Corporate Address

Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenoviabio.com

Copyright © 2023 Eyenovia, Inc. All rights reserved.
  • Twitter
  • Facebook
  • LinkedIn
  • Contact
  • Safe Harbor
  • Privacy Policy
  • Terms of Use
Scroll to top